Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c; Guides Lower
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $6.21 +2.64%
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $68 million versus the consensus estimate of $70.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2022 revenue of $240-280 million, versus the consensus of $313.62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
- RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
